Brii Bio commits $100 million for COVID-19 late-stage MAb combo therapy, BRII-196/BRII-198

Sino-American company Brii Biosciences (HK: 2137) today announced that it is committing an additional $100 million to advance global regulatory filings and commercial efforts for its investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, BRII-196/BRII-198.

Brii Bio’s shares closed up 3.4% at HK$42.40, having hit HK$44.15 in earlier trading on the news.

"Following on the heels of a positive Phase III readout of the ACTIV-2 trial, and as countries around the world continue to face a significant resurgence of COVID-19 cases, we are doubling down on our efforts to bring BRII-196/BRII-198 to a broad range of patients as a promising potential new treatment option for COVID-19," said Zhi Hong, chairman and chief executive of Brii Biosciences, adding: "This investment reinforces the company's mission, building on the highly effective clinical outcomes, as we accelerate our strategic efforts to pursue regulatory filings, expand manufacturing and supply capabilities and establish key collaborations in both established and emerging global markets to pave a clear and compelling path to commercialization."